[Effect of Biweekly-DCF Neoadjuvant Chemotherapy on Skeletal Muscle Mass of Esophageal Cancer Patients].

Yuta Sato,Yoshihiro Tanaka,Takeharu Imai, Hidenori Ojio, Junichi Mase,Yuji Hatanaka,Tomonari Suetsugu, Hironori Fujii,Naoki Okumura,Nobuhisa Matsuhashi,Takao Takahashi,Kazuhiro Yoshida

Gan to kagaku ryoho. Cancer & chemotherapy（2022）

引用 0|浏览6

暂无评分

摘要

In preoperative chemotherapy for esophageal cancer, the incidence of hematological toxicity was significantly higher in patients with low skeletal muscle mass. Thus, skeletal muscle mass may be a marker for determining optimal anticancer drug dosage.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要